2016
Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer.
Galsky M, Hahn N, Albany C, Fleming M, Starodub A, Twardowski P, Pal S, Hauke R, Sonpavde G, Oh W, Bhardwaj N, Gnjatic S, Kim-Schulze S, Liu Z. Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer. Journal Of Clinical Oncology 2016, 34: 357-357. DOI: 10.1200/jco.2016.34.2_suppl.357.Peer-Reviewed Original ResearchImmune checkpoint blockadeProgression-free survivalCycles of GCCTLA4 blockadeCheckpoint blockadeGrade 3Adverse eventsPhase II trial of gemcitabineAnti-PD-1/PD-L1 antibodiesAntigen-specific T cell immunityCirculating immune cell subsetsImmune-related adverse eventsMedian progression-free survivalImmunomodulatory effectsResponse rateTrial of gemcitabineCycles of gemcitabineMetastatic urothelial cancerLocalized bladder cancerCD8 T cellsImmunogenic cell deathMedian Follow-UpPhase II trialT cell immunityImmune cell subsets
2004
A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer
Kaufman D, Carducci M, Kuzel T, Todd M, Oh W, Smith M, Ye Z, Nicol S, Stadler W. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urologic Oncology Seminars And Original Investigations 2004, 22: 393-397. PMID: 15464919, DOI: 10.1016/j.urolonc.2004.01.002.Peer-Reviewed Original ResearchConceptsMetastatic urothelial cancerUrothelial cancerResponse rateMulti-institutional phase II trialPhase II trial of gemcitabineTrial of gemcitabineAdequate organ functionWorld Health OrganizationPoor renal functionOverall response ratePartial responseCombined gemcitabineMedian survivalPrognostic groupsInsufficiency patientsPerformance statusRenal functionTherapy statusGrade 3Treated patientsBiweekly schedulePatientsRoutine useOrgan functionGemcitabine
2000
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer.
Kaufman D, Raghavan D, Carducci M, Levine E, Murphy B, Aisner J, Kuzel T, Nicol S, Oh W, Stadler W. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. Journal Of Clinical Oncology 2000, 18: 1921-7. PMID: 10784633, DOI: 10.1200/jco.2000.18.9.1921.Peer-Reviewed Original ResearchConceptsMetastatic urothelial cancerTreatment of metastatic urothelial cancerChemotherapy-naive patientsUrothelial cancerMedian time to treatment failurePhase II trial of gemcitabineTreatment of chemotherapy-naive patientsDay 1Time to treatment failureStage IV carcinomaTrial of gemcitabineCombination of gemcitabinePhase II trialClinical safety profileHematologic toxicityCisplatin doseIV carcinomaPartial responseMedian survivalTreatment failureSafety profileSevere toxicityGemcitabineChemotherapeutic agentsDisease progression
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply